This systematic review and network meta-analysis evaluated the comparative efficacy and safety of subcutaneously administered tirzepatide versus semaglutide in adults with type 2 diabetes. The analysis included data from multiple randomized controlled trials, assessing outcomes such as glycemic control (HbA1c reduction), weight loss, and adverse events. Results indicated that tirzepatide
